Company intelligence / Profile preview

Lipogems

Ownership: Private
Development stage: Phase 3

Overview

Lipogems’ microfragmented fat technology has been used in over 50,000 procedures worldwide. The system is FDA-cleared as a 510(k) device for the harvest, concentration, and transfer of autologous adipose tissue. Over 140 peer-reviewed publications support its safety and efficacy with up to five years of follow-up data in orthopedics. An ongoing U.S. FDA IDE study is evaluating its use specifically for knee osteoarthritis compared to corticosteroids.

Therapeutic areas: OtherDermatologyRheumatology
Modalities: DeviceCell therapy (specifically, autologous microfragmented adipose tissue)
Industry: Surgical Medical Devices

Drug pipeline

1 asset

MicroFat

Phase 3

Indications: Knee osteoarthritis

Partnerships

Collaborations with physicians, surgeons, scientific researchers globallyAcademic collaborations with international research centers

Beyond the preview

Go deeper on Lipogems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipogems.